Horizon Scanning in Oncology - Reports and Fact Sheets
Decision Support Documents
Within the scope of the Horizon Scanning in Oncology project, the LBI-HTA periodically published assessments until 2019 on novel cancer drugs with a likely therapeutical and/or financial outcome. These assessments served as decision aids for funding agencies and the decision-making network "HTA in hospitals " alike.
Since January 2020, monthly Fact Sheets will be conducted concerning all pharmaceutical oncological therapies that have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
Oncology Fact Sheets since January 2020:
Fact Sheet No. 12 (Mai 2020)
Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer New!
Fact Sheet No. 11 (Mai 2020)
Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer New!
Fact Sheet No. 10 (April 2020)
Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)
Fact Sheet No. 5 (March 2020)
Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)
Fact Sheet No. 4 (February 2020)
Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC)
Fact Sheet No. 2 (January 2020)
Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC)
Fact Sheet No. 1 (January 2020)
Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions
Publikation series October 2009 - December 2020 (in English):
DSD HSO No. 51
Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy
DSD HSO No. 32
Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole
DSD HSO No. 11/ 1st update 2011
Panitumumab (Vectibix®) as 1st-line combination therapy for the treatment of WT KRAS metastatic colorectal cancer
DSD HSO No. 6/ 1st update 2011
Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011
Contact: Nicole Grössmann